首页> Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer> Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14).

Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14).

导出原文传递

翻译打印收藏纠错

第一作者： Solange,Peters

第一单位： Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

作者： Solange,Peters ^[1] ; Enriqueta,Felip ^[2] ; Urania,Dafni ^[3] ; Amanda,Tufman ^[4] ; Matthias,Guckenberger ^[5] ; Ruth,Álvarez ^[6] ; Ernest,Nadal ^[7] ; Annemarie,Becker ^[8] ; Hansjörg,Vees ^[9] ; Miklos,Pless ^[10] ; Alex,Martinez-Marti ^[2] ; Maarten,Lambrecht ^[11] ; Nicolaus,Andratschke ^[5] ; Zoi,Tsourti ^[12] ; Anne-Christine,Piguet ^[13] ; Heidi,Roschitzki-Voser ^[13] ; Adrian,Gasca-Ruchti ^[13] ; Johan,Vansteenkiste ^[14] ; Rolf A,Stahel ^[15] ; Dirk,De Ruysscher ^[16]

作者单位： Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. ^[1] Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. ^[2] Frontier Science Foundation-Hellas, Athens, Greece; National and Kapodistrian University of Athens, Athens, Greece. ^[3] Department of Internal Medicine V, Ludwig-Maximilians University Munich, Munich, Germany; German Center for Lung Research Comprehensive Pneumology Center Munich, Munich, Germany. ^[4] Department for Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. ^[5] Department of Medical Oncology, Hospital Virgen De La Salud, Toledo, Spain. ^[6] Department of Medical Oncology, Catalan Institute of Oncology, Institut d'Investigació Biomédica de Bellvitge L'Hospitalet, Barcelona, Spain. ^[7] Department of Respiratory Diseases, Amsterdam University Medical Center, Amsterdam, The Netherlands. ^[8] Radiation Oncology, Clinic Hirslanden, Zurich, Switzerland. ^[9] Medical Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland. ^[10] Department of Radiotherapy-Oncology, University Hospitals Leuven, Leuven, Belgium. ^[11] Frontier Science Foundation-Hellas, Athens, Greece. ^[12] European Thoracic Oncology Platform, Bern, Switzerland. ^[13] Department of Respiratory Diseases, University Hospital Katholieke Universiteit Leuven, Leuven, Belgium. ^[14] European Thoracic Oncology Platform, Bern, Switzerland. Electronic address: Rolf.Stahel@etop-eu.org. ^[15] Department of Radiation Oncology (Maastro), Maastricht University Medical Center, GROW School for Oncology, Maastricht, The Netherlands. ^[16]

关键词 Chemoradiotherapy Immune checkpoint inhibition NSCLC Nivolumab

医学主题词抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);无病生存(Disease-Free Survival);人类(Humans);肺肿瘤(Lung Neoplasms);肿瘤分期(Neoplasm Staging);参考标准(Reference Standards)

DOI 10.1016/j.jtho.2020.10.129

PMID 33188912

发布时间 2021-05-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交